Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Menactra in Healthy Subjects in India
NCT01086969Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2010
- Primary completion
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal A conjugate vaccine in meningococcal infection and meningitis, sponsored by Sanofi. Primary endpoints: Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination, Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination and 2 more. Started Jun 2010; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal infectionmeningitis
Beyond the preview
Go deeper on NCT01086969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086969.